- Home
- CUE vs COEP Comparison
CUE vs COEP Comparison
Compare CUE & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- COEP
- Stock Information
- Founded
- CUE 2014
- COEP 2017
- Country
- CUE United States
- COEP United States
- Employees
- CUE N/A
- COEP N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CUE Health Care
- COEP Health Care
- Exchange
- CUE Nasdaq
- COEP Nasdaq
- Market Cap
- CUE 59.5M
- COEP 62.4M
- IPO Year
- CUE 2018
- COEP N/A
- Fundamental
- Price
- CUE $0.72
- COEP $12.60
- Analyst Decision
- CUE Strong Buy
- COEP
- Analyst Count
- CUE 2
- COEP 0
- Target Price
- CUE $3.00
- COEP N/A
- AVG Volume (30 Days)
- CUE 132.0K
- COEP 39.1K
- Earning Date
- CUE 11-13-2025
- COEP 11-12-2025
- Dividend Yield
- CUE N/A
- COEP N/A
- EPS Growth
- CUE N/A
- COEP N/A
- EPS
- CUE N/A
- COEP N/A
- Revenue
- CUE $8,286,000.00
- COEP $263,555.00
- Revenue This Year
- CUE N/A
- COEP N/A
- Revenue Next Year
- CUE $13.27
- COEP N/A
- P/E Ratio
- CUE N/A
- COEP N/A
- Revenue Growth
- CUE N/A
- COEP N/A
- 52 Week Low
- CUE $0.45
- COEP $2.31
- 52 Week High
- CUE $1.99
- COEP $14.70
- Technical
- Relative Strength Index (RSI)
- CUE 34.73
- COEP 51.40
- Support Level
- CUE $0.77
- COEP $12.09
- Resistance Level
- CUE $0.78
- COEP $13.25
- Average True Range (ATR)
- CUE 0.03
- COEP 0.73
- MACD
- CUE -0.01
- COEP -0.12
- Stochastic Oscillator
- CUE 9.53
- COEP 45.78
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.